MediSieve

MediSieve is a biotechnology company developing selective magnetic blood filtration using engineered particles that bind specific circulating biological targets.

Its extracorporeal system combines target-specific magnetic beads with a capture device designed to remove bound substances before blood returns to the patient. A lead application aims to deplete neutralising antibodies against adeno-associated virus vectors, potentially expanding access to AAV-based gene therapies.

The company has completed initial clinical safety studies of its filtration platform.